Nestle Urolithin Suspension Patent B2 Using Xanthan Gum in Aqueous Matrix
Summary
USPTO granted Patent US12605360B2 to Societe des Produits Nestle S.A. on April 21, 2026, covering compositions and methods for using xanthan gum to stabilize at least one urolithin, such as Urolithin A, in an aqueous matrix. The patent discloses a powder formulation that can be reconstituted in a liquid such as water to form a beverage, with the xanthan gum maintaining the majority of the urolithin in suspension. The patent names five inventors and contains 13 claims.
“A powder contains xanthan gum and at least one urolithin, such as Urolithin A; and the powder can be reconstituted in a liquid such as water to form a liquid composition for oral consumption, such as a beverage.”
About this source
GovPing monitors USPTO Patent Grants - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 26 changes logged to date.
What changed
USPTO issued Patent US12605360B2 to Societe des Produits Nestle S.A., covering a powder composition containing xanthan gum and at least one urolithin that can be reconstituted in water to form a liquid beverage. The xanthan gum serves as a stabilizer to keep the urolithin in suspension in the liquid composition for oral consumption. The patent also covers methods of making the powder, making the liquid composition, and using the composition prophylactically or therapeutically.
Competitors developing urolithin-based beverages or nutritional supplements should review this patent for freedom-to-operate considerations, as Nestle now holds enforceable claims covering xanthan gum stabilization of urolithins in aqueous suspensions for oral consumption. The patent may affect product development strategies for anti-aging and mitochondrial health supplements.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
Grant US12605360B2 Kind: B2 Apr 21, 2026
Assignee
Societe des Produits Nestle S.A.
Inventors
Anupama Dattatreya, Vivek Dilip Savant, Loretta Grant, Sanjay Gupta
Abstract
A powder contains xanthan gum and at least one urolithin, such as Urolithin A; and the powder can be reconstituted in a liquid such as water to form a liquid composition for oral consumption, such as a beverage. The xanthan gum can keep the majority of the at least one urolithin in suspension in the beverage. The resultant liquid composition for oral consumption is another aspect of the present disclosure, as well as methods of making the powder, making the liquid composition for oral consumption, and using the powder or liquid composition prophylactically or therapeutically.
CPC Classifications
A61K 31/366
Filing Date
2021-09-22
Application No.
18246442
Claims
13
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.